D.E. Shaw & Co’s Sage Therapeutics SAGE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-41,100
| Closed | -$297K | – | 4811 |
|
|
2024
Q3 | $297K | Sell |
41,100
-5,000
| -11% | -$45.8K | ﹤0.01% | 3981 |
|
|
2024
Q2 | $501K | Buy |
+46,100
| New | +$591K | ﹤0.01% | 3623 |
|
|
2023
Q1 | – | Sell |
-20,000
| Closed | -$763K | – | 4808 |
|
|
2022
Q4 | $763K | Hold |
20,000
| – | – | ﹤0.01% | 3627 |
|
|
2022
Q3 | $783K | Hold |
20,000
| – | – | ﹤0.01% | 3764 |
|
|
2022
Q2 | $646K | Hold |
20,000
| – | – | ﹤0.01% | 3938 |
|
|
2022
Q1 | $662K | Buy |
+20,000
| New | +$752K | ﹤0.01% | 4201 |
|
|
2021
Q3 | – | Sell |
-75,000
| Closed | -$4.26M | – | 5197 |
|
|
2021
Q2 | $4.26M | Buy |
+75,000
| New | +$5.3M | ﹤0.01% | 2185 |
|
|
2020
Q3 | – | Sell |
-30,000
| Closed | -$1.25M | – | 4117 |
|
|
2020
Q2 | $1.25M | Buy |
+30,000
| New | +$1.09M | ﹤0.01% | 2777 |
|
|
2020
Q1 | – | Sell |
-32,000
| Closed | -$2.31M | – | 4211 |
|
|
2019
Q4 | $2.31M | Hold |
32,000
| – | – | ﹤0.01% | 2347 |
|
|
2019
Q3 | $4.49M | Hold |
32,000
| – | – | 0.01% | 1727 |
|
|
2019
Q2 | $5.86M | Hold |
32,000
| – | – | 0.01% | 1487 |
|
|
2019
Q1 | $5.09M | Sell |
32,000
-5,000
| -14% | -$724K | 0.01% | 1540 |
|
|
2018
Q4 | $3.54M | Buy |
37,000
+16,500
| +80% | +$1.89M | ﹤0.01% | 1739 |
|
|
2018
Q3 | $2.9M | Buy |
20,500
+5,000
| +32% | +$772K | ﹤0.01% | 1943 |
|
|
2018
Q2 | $2.43M | Buy |
15,500
+500
| +3% | +$78.5K | ﹤0.01% | 2079 |
|
|
2018
Q1 | $2.42M | Buy |
+15,000
| New | +$2.55M | ﹤0.01% | 1925 |
|
|
2016
Q4 | – | Sell |
-20,000
| Closed | -$921K | – | 3583 |
|
|
2016
Q3 | $921K | Buy |
+20,000
| New | +$814K | ﹤0.01% | 2431 |
|
Other funds holding SAGE
IA
HNB
D.E. Shaw & Co's SAGE Position: Q3 2025 in Review
D.E. Shaw & Co sold out of Sage Therapeutics (SAGE) in Q3 2025, closing a stake of 1,917,284 shares — an estimated $17.5M sold.
D.E. Shaw & Co first reported a position in SAGE in Q4 2015 and held it in 34 quarters. The position peaked at $190M in Q4 2020. 5 funds tracked by Wall St. Rank hold SAGE as of Q3 2025.
- D.E. Shaw & Co reported no remaining Sage Therapeutics position as of Q3 2025 after selling out during the quarter.
- D.E. Shaw & Co sold 1,917,284 Sage Therapeutics shares in Q3 2025, an estimated $17.5M.
- D.E. Shaw & Co first reported a position in Sage Therapeutics in Q4 2015 and held it in 34 quarters.
- D.E. Shaw & Co's Sage Therapeutics position peaked at $190M in Q4 2020.
- 5 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2025.
Based on D.E. Shaw & Co's 13F filing for Q3 2025, filed 14 Nov 2025.